Two Sigma Advisers
EGRX

Two Sigma Advisers’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Two Sigma Advisers’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-185,058
Closed -$690K – 2594
2024
Q3 		$690K Sell
185,058
-39,759
-18% -$190K ﹤0.01% 1572
2024
Q2 		$1.26M Sell
224,817
-11,500
-5% -$50.1K ﹤0.01% 1431
2024
Q1 		$1.24M Buy
236,317
+14,300
+6% +$78.5K ﹤0.01% 1464
2023
Q4 		$1.16M Buy
222,017
+199,500
+886% +$1.97M ﹤0.01% 1568
2023
Q3 		$355K Buy
+22,517
New +$405K ﹤0.01% 1922
2021
Q4 		– Sell
-4,300
Closed -$240K – 2842
2021
Q3 		$240K Sell
4,300
-22,800
-84% -$1.12M ﹤0.01% 2189
2021
Q2 		$1.16M Sell
27,100
-84,600
-76% -$3.49M ﹤0.01% 1568
2021
Q1 		$4.66M Buy
111,700
+29,700
+36% +$1.38M 0.01% 878
2020
Q4 		$3.82M Buy
82,000
+66,900
+443% +$3.13M 0.01% 932
2020
Q3 		$641K Buy
15,100
+3,500
+30% +$153K ﹤0.01% 1710
2020
Q2 		$557K Buy
+11,600
New +$579K ﹤0.01% 1848
2019
Q3 		– Sell
-10,600
Closed -$590K – 2429
2019
Q2 		$590K Buy
10,600
+4,200
+66% +$219K ﹤0.01% 1743
2019
Q1 		$323K Buy
+6,400
New +$285K ﹤0.01% 1963
2018
Q3 		– Sell
-6,000
Closed -$454K – 2439
2018
Q2 		$454K Buy
+6,000
New +$377K ﹤0.01% 1956
2017
Q4 		– Sell
-4,800
Closed -$286K – 2407
2017
Q3 		$286K Buy
4,800
+1,500
+45% +$90.7K ﹤0.01% 1942
2017
Q2 		$260K Buy
+3,300
New +$270K ﹤0.01% 2040
2016
Q1 		– Sell
-36,491
Closed -$3.24M – 2158
2015
Q4 		$3.24M Sell
36,491
-23,709
-39% -$1.87M 0.02% 580
2015
Q3 		$4.47M Buy
60,200
+49,300
+452% +$4.1M 0.03% 500
2015
Q2 		$881K Buy
+10,900
New +$710K 0.01% 1178

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Two Sigma Advisers's EGRX Position: Q4 2024 in Review

Two Sigma Advisers sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 185,058 shares — an estimated $690K sold.

Two Sigma Advisers first reported a position in EGRX in Q2 2015 and held it in 19 quarters. The position peaked at $4.66M in Q1 2021. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Two Sigma Advisers reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 185,058 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $690K.
  • Two Sigma Advisers first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 19 quarters.
  • Two Sigma Advisers's Eagle Pharmaceuticals, Inc. position peaked at $4.66M in Q1 2021.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Two Sigma Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.